{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:27Z","timestamp":1786982727924,"version":"build-2736575974"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Thea Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01241-9","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:35:32Z","timestamp":1758274532000},"page":"2653-2671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost"],"prefix":"10.1007","volume":"14","author":[{"given":"Deepinder K.","family":"Dhaliwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti Garg","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Paul Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba A.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell E.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"1241_CR1","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma preferred practice pattern\u00ae. Ophthalmology. 2021;128:P71\u2013150.","journal-title":"Ophthalmology"},{"key":"1241_CR2","volume":"9","author":"GBD Blindness and Vision Impairment Collaborators","year":"2021","unstructured":"GBD Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u2013e60.","journal-title":"Lancet Glob Health"},{"key":"1241_CR3","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"1241_CR4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamaophthalmol.2024.3884","volume":"142","author":"JR Ehrlich","year":"2024","unstructured":"Ehrlich JR, Burke-Conte Z, Wittenborn JS, Saaddine J, Omura JD, Friedman DS, et al. Prevalence of glaucoma among US adults in 2022. JAMA Ophthalmol. 2024;142:1046\u201353.","journal-title":"JAMA Ophthalmol"},{"key":"1241_CR5","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.12.10.18","volume":"12","author":"SS Davuluru","year":"2023","unstructured":"Davuluru SS, Jess AT, Kim JSB, Yoo K, Nguyen V, Xu BY. Identifying, understanding, and addressing disparities in glaucoma care in the United States. Transl Vis Sci Technol. 2023;12:18.","journal-title":"Transl Vis Sci Technol"},{"issue":"303\u201314","key":"1241_CR6","volume":"154","author":"TS Vajaranant","year":"2012","unstructured":"Vajaranant TS, Wu S, Torres M, Varma R. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. Am J Ophthalmol. 2012;154(303\u201314):e3.","journal-title":"Am J Ophthalmol"},{"key":"1241_CR7","unstructured":"Vision & Eye Health Surveillance System (VEHSS), Centers for Disease Control and Prevention (CDC), Vision Health Initiative. Percentage of adults ever told by a doctor or other health professional they had glaucoma (NHIS Adult Module). CDC. https:\/\/ddt-vehss.cdc.gov\/LP?Level1=Glaucoma."},{"key":"1241_CR8","unstructured":"Projected population by age group and sex. United States Census Bureau. https:\/\/www2.census.gov\/programs-surveys\/popproj\/tables\/2023\/2023-summary-tables\/np2023-t2.xlsx."},{"key":"1241_CR9","unstructured":"Glaucoma: NEI looks ahead. National Eye Institute. https:\/\/medialibrary.nei.nih.gov\/sites\/default\/files\/media-images\/NEI-medialibrary-6248268.jpg."},{"key":"1241_CR10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41433-019-0637-2","volume":"34","author":"A Kastner","year":"2020","unstructured":"Kastner A, King AJ. Advanced glaucoma at diagnosis: current perspectives. Eye (Lond). 2020;34:116\u201328.","journal-title":"Eye (Lond)"},{"key":"1241_CR11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ogla.2020.09.002","volume":"4","author":"GF Schwartz","year":"2021","unstructured":"Schwartz GF, Patel A, Naik R, Lunacsek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmol Glaucoma. 2021;4:117\u201325.","journal-title":"Ophthalmol Glaucoma"},{"key":"1241_CR12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/IJG.0000000000001730","volume":"30","author":"AR Patel","year":"2021","unstructured":"Patel AR, Schwartz GF, Campbell JH, Chen CC, McGuiness CB, Multani JK, et al. Economic and clinical burden associated with intensification of glaucoma topical therapy: a US claims-based analysis. J Glaucoma. 2021;30:242\u201350.","journal-title":"J Glaucoma"},{"key":"1241_CR13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ogla.2020.12.007","volume":"4","author":"V Shih","year":"2021","unstructured":"Shih V, Parekh M, Multani JK, McGuiness CB, Chen CC, Campbell JH, et al. Clinical and economic burden of glaucoma by disease severity: a United States claims-based analysis. Ophthalmol Glaucoma. 2021;4:490\u2013503.","journal-title":"Ophthalmol Glaucoma"},{"key":"1241_CR14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.survophthal.2020.09.005","volume":"66","author":"P Nichani","year":"2021","unstructured":"Nichani P, Popovic MM, Schlenker MB, Park J, Ahmed IIK. Microinvasive glaucoma surgery: a review of 3476 eyes. Surv Ophthalmol. 2021;66:714\u201342.","journal-title":"Surv Ophthalmol"},{"key":"1241_CR15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ophtha.2022.07.003","volume":"129","author":"SJ Gedde","year":"2022","unstructured":"Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed II, et al. Treatment outcomes in the primary tube versus trabeculectomy study after 5 years of follow-up. Ophthalmology. 2022;129:1344\u201356.","journal-title":"Ophthalmology"},{"key":"1241_CR16","volume":"13","author":"FM Wagner","year":"2023","unstructured":"Wagner FM, Schuster AK, Kianusch K, Stingl J, Pfeiffer N, Hoffmann EM. Long-term success after trabeculectomy in open-angle glaucoma: results of a retrospective cohort study. BMJ Open. 2023;13:e068403.","journal-title":"BMJ Open"},{"key":"1241_CR17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ceo.12452","volume":"43","author":"DM Woo","year":"2015","unstructured":"Woo DM, Healey PR, Graham SL, Goldberg I. Intraocular pressure-lowering medications and long-term outcomes of selective laser trabeculoplasty. Clin Exp Ophthalmol. 2015;43:320\u20137.","journal-title":"Clin Exp Ophthalmol"},{"key":"1241_CR18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/2008-322X.150814","volume":"9","author":"AS Khouri","year":"2014","unstructured":"Khouri AS, Lari HB, Berezina TL, Maltzman B, Fechtner RD. Long term efficacy of repeat selective laser trabeculoplasty. J Ophthalmic Vis Res. 2014;9:444\u20138.","journal-title":"J Ophthalmic Vis Res"},{"key":"1241_CR19","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","volume":"12","author":"NM Radcliffe","year":"2023","unstructured":"Radcliffe NM, Shah M, Samuelson TW. Challenging the \u201ctopical medications-first\u201d approach to glaucoma: a treatment paradigm in evolution. Ophthalmol Ther. 2023;12:2823\u201339.","journal-title":"Ophthalmol Ther"},{"key":"1241_CR20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12886-022-02431-w","volume":"22","author":"G Birhanu","year":"2022","unstructured":"Birhanu G, Tegegne AS. Predictors for elevation of intraocular pressure (IOP) on glaucoma patients; a retrospective cohort study design. BMC Ophthalmol. 2022;22:254.","journal-title":"BMC Ophthalmol"},{"key":"1241_CR21","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12040514","volume":"12","author":"AC Zaharia","year":"2022","unstructured":"Zaharia AC, Dumitrescu OM, Radu M, Rogoz RE. Adherence to therapy in glaucoma treatment-a review. J Pers Med. 2022;12:514.","journal-title":"J Pers Med"},{"key":"1241_CR22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","volume":"112","author":"AL Robin","year":"2005","unstructured":"Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863\u20138.","journal-title":"Ophthalmology"},{"key":"1241_CR23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1442-9071.2012.02781.x","volume":"40","author":"S Ghosh","year":"2012","unstructured":"Ghosh S, O\u2019Hare F, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40:675\u201381.","journal-title":"Clin Exp Ophthalmol"},{"key":"1241_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","volume":"36","author":"MH Goldstein","year":"2022","unstructured":"Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022;36:361\u20138.","journal-title":"Eye (Lond)"},{"key":"1241_CR25","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society terminology and guidelines for glaucoma, 5th edition. Br J Ophthalmol. 2021;105:1\u2013169.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"1241_CR26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","volume":"102","author":"DW Steven","year":"2018","unstructured":"Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102:1497\u2013503.","journal-title":"Br J Ophthalmol"},{"key":"1241_CR27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"1241_CR28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C Baudouin","year":"2008","unstructured":"Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716\u201326.","journal-title":"Acta Ophthalmol"},{"key":"1241_CR29","first-page":"112067212211443","volume":"33","author":"M Parkkari","year":"2022","unstructured":"Parkkari M, Purola P, Uusitalo H. Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland. Eur J Ophthalmol. 2022;33:11206721221144339.","journal-title":"Eur J Ophthalmol"},{"key":"1241_CR30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S229815","volume":"14","author":"AL Mylla Boso","year":"2020","unstructured":"Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol. 2020;14:103\u201311.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jtos.2024.08.001","volume":"34","author":"MY Kahook","year":"2024","unstructured":"Kahook MY, Rapuano CJ, Messmer EM, Radcliffe NM, Galor A, Baudouin C. Preservatives and ocular surface disease: a review. Ocul Surf. 2024;34:213\u201324.","journal-title":"Ocul Surf"},{"key":"1241_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109121","volume":"221","author":"T Suarez-Cortes","year":"2022","unstructured":"Suarez-Cortes T, Merino-Inda N, Benitez-Del-Castillo JM. Tear and ocular surface disease biomarkers: a diagnostic and clinical perspective for ocular allergies and dry eye disease. Exp Eye Res. 2022;221:109121.","journal-title":"Exp Eye Res"},{"key":"1241_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","volume":"202","author":"R Dana","year":"2019","unstructured":"Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47\u201354.","journal-title":"Am J Ophthalmol"},{"key":"1241_CR34","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/532378","volume":"2014","author":"L Ottobelli","year":"2014","unstructured":"Ottobelli L, Fogagnolo P, Guerini M, Rossetti L. Age-related changes of the ocular surface: a hospital setting-based retrospective study. J Ophthalmol. 2014;2014:532378.","journal-title":"J Ophthalmol"},{"key":"1241_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/OPTO.S411390","volume":"15","author":"NY Belie","year":"2023","unstructured":"Belie NY, Ayele FA, Mengist B, Alemayehu AM, Assem AS, Fekadu SA, et al. Patients\u2019 satisfaction with topical anti-glaucoma medications and associated factors at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021. Clin Optom (Auckl). 2023;15:139\u201346.","journal-title":"Clin Optom (Auckl)"},{"key":"1241_CR36","first-page":"785","volume":"9","author":"HG Lemij","year":"2015","unstructured":"Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785\u201393.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR37","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.2147\/OPTH.S269586","volume":"14","author":"I Stalmans","year":"2020","unstructured":"Stalmans I, Lemij H, Clarke J, Baudouin C, Goal Study Group. Signs and symptoms of ocular surface disease: the reasons for patient dissatisfaction with glaucoma treatments. Clin Ophthalmol. 2020;14:3675\u201380.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0420.2007.00882.x","volume":"85","author":"A Chawla","year":"2007","unstructured":"Chawla A, McGalliard JN, Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85:464.","journal-title":"Acta Ophthalmol Scand"},{"key":"1241_CR39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0181-5512(08)71431-1","volume":"31","author":"C Baudouin","year":"2008","unstructured":"Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC, Brouquet Y, Bassols A, et al. Severe impairment of health-related quality of life in patients suffering from ocular surface diseases. J Fr Ophtalmol. 2008;31:369\u201378.","journal-title":"J Fr Ophtalmol"},{"key":"1241_CR40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/ICU.0b013e32833a8c15","volume":"21","author":"NJ Friedman","year":"2010","unstructured":"Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21:310\u20136.","journal-title":"Curr Opin Ophthalmol"},{"key":"1241_CR41","volume":"2013","author":"S Kastelan","year":"2013","unstructured":"Kastelan S, Tomic M, Metez Soldo K, Salopek-Rabatic J. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328.","journal-title":"Biomed Res Int"},{"key":"1241_CR42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4274\/tjo.galenos.2019.29000","volume":"50","author":"S Kumar","year":"2020","unstructured":"Kumar S, Singh T, Ichhpujani P, Vohra S, Thakur S. Correlation of ocular surface disease and quality of life in Indian glaucoma patients: BAC-preserved versus BAC-free travoprost. Turk J Ophthalmol. 2020;50:75\u201381.","journal-title":"Turk J Ophthalmol"},{"key":"1241_CR43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283597","volume":"18","author":"S Ocansey","year":"2023","unstructured":"Ocansey S, Antiri EO, Abraham CH, Abu EK. Dry eye symptom questionnaires show adequate measurement precision and psychometric validity for clinical assessment of vision-related quality of life in glaucoma patients. PLoS ONE. 2023;18:e0283597.","journal-title":"PLoS ONE"},{"key":"1241_CR44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jfo.2018.06.007","volume":"42","author":"K Leila","year":"2019","unstructured":"Leila K, Gatfaoui F, Mahjoub A, Yakoubi S, Krifa F, Ghorbel M, et al. Impact of glaucoma medications and ocular surface disease on the quality of life of glaucoma patients in the district of Sousse (Tunisia). J Fr Ophtalmol. 2019;42:464\u201370.","journal-title":"J Fr Ophtalmol"},{"key":"1241_CR45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/jop.2011.0159","volume":"29","author":"GC Rossi","year":"2013","unstructured":"Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29:390\u20134.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1241_CR46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovic","year":"2007","unstructured":"Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"1\u20139","key":"1241_CR47","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1\u20139):e2.","journal-title":"Am J Ophthalmol"},{"key":"1241_CR48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.17925\/EOR.2011.05.02.116","volume":"5","author":"P Denis","year":"2011","unstructured":"Denis P. Adverse effects, adherence and cost\u2013benefits in glaucoma treatment. Eur Ophthal Rev. 2011;5:116\u201322.","journal-title":"Eur Ophthal Rev"},{"key":"1241_CR49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aos.16599","volume":"102","author":"G Johannesson","year":"2024","unstructured":"Johannesson G, Stille U, Taube AB, Karlsson M, Kalaboukhova L, Bergstrom A, et al. Guidelines for the management of open-angle glaucoma: National Program Area Eye Diseases, National Working Group Glaucoma. Acta Ophthalmol. 2024;102:135\u201350.","journal-title":"Acta Ophthalmol"},{"key":"1241_CR50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/jcm12010151","volume":"12","author":"B Cvenkel","year":"2022","unstructured":"Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: a narrative review. J Clin Med. 2022;12:151.","journal-title":"J Clin Med"},{"key":"1241_CR51","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1080\/14656566.2020.1795130","volume":"21","author":"WS Shalaby","year":"2020","unstructured":"Shalaby WS, Shankar V, Razeghinejad R, Katz LJ. Current and new pharmacotherapeutic approaches for glaucoma. Expert Opin Pharmacother. 2020;21:2027\u201340.","journal-title":"Expert Opin Pharmacother"},{"key":"1241_CR52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323.","journal-title":"Br J Ophthalmol"},{"key":"1241_CR53","unstructured":"NDA 19-463\/S-019 (Timoptic in Ocudose). Food and Drug Administration; 1998 [cited March 1998]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/19-463S019.pdf."},{"key":"1241_CR54","unstructured":"Timoptic\u00ae (timolol maleate ophthalmic solution) in Ocudose\u00ae [prescribing information]. Whitehouse Station: Merck & Co., Inc.; 1986."},{"key":"1241_CR55","unstructured":"First preservative-free prostaglandin treatment approved. Ophthalmology Times Europe. [cited 2008 June 1]. https:\/\/europe.ophthalmologytimes.com\/view\/first-preservative-free-prostaglandin-treatment-approved-0."},{"key":"1241_CR56","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2147\/OPTH.S414015","volume":"17","author":"J Bacharach","year":"2023","unstructured":"Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-free versus benzalkonium chloride-preserved latanoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension: a phase 3 US clinical trial. Clin Ophthalmol. 2023;17:2575\u201388.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR57","unstructured":"Zioptan (talfuprost ophthalmic solution) [prescribing information]. Waltham: Th\u00e9a Pharma, Inc.; 2022."},{"key":"1241_CR58","unstructured":"Iyuzeh (latanoprost ophthalmic solution) [prescribing information]. Waltham: Th\u00e9a Pharma, Inc.; 2022."},{"key":"1241_CR59","unstructured":"COSOPT\u00ae PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) [prescribing information]. Waltham: Th\u00e9a Pharma, Inc.; 2022."},{"key":"1241_CR60","unstructured":"TRUSOPT Preservative-Free (dorzolamide hydrochloride) [summary of product characteristics]. St Albans: Santen UK Limited; 2023."},{"key":"1241_CR61","unstructured":"American Optometric Association (AOA). Care of the patient with primary open-angle glaucoma. First edition. AOA website. [cited 2024]. https:\/\/www.aoa.org\/documents\/EBO\/GLAUCOMA\/FINAL_EBO_Glaucoma_Guildline_digital_10_28_24.pdf."},{"key":"1241_CR62","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2147\/OPTH.S211611","volume":"13","author":"K Walsh","year":"2019","unstructured":"Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019;13:1409\u201325.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR63","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/IJG.0000000000001728","volume":"30","author":"E Barayev","year":"2021","unstructured":"Barayev E, Geffen N, Nahum Y, Gershoni A. Changes in prices and eye-care providers prescribing patterns of glaucoma medications in the United States between 2013 and 2019. J Glaucoma. 2021;30:e83\u20139.","journal-title":"J Glaucoma"},{"key":"1241_CR64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jtos.2023.05.012","volume":"29","author":"M Kolko","year":"2023","unstructured":"Kolko M, Gazzard G, Baudouin C, Beier S, Brignole-Baudouin F, Cvenkel B, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocul Surf. 2023;29:456\u201368.","journal-title":"Ocul Surf"},{"key":"1241_CR65","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.3390\/pharmaceutics14102176","volume":"14","author":"K Iskandar","year":"2022","unstructured":"Iskandar K, Marchin L, Kodjikian L, Rocher M, Roques C. Highlighting the microbial contamination of the dropper tip and cap of in-use eye drops, the associated contributory factors, and the risk of infection: a past-30-years literature review. Pharmaceutics. 2022;14:2176.","journal-title":"Pharmaceutics"},{"key":"1241_CR66","unstructured":"Holpuch A. What to know about the recent eyedrops recalls. New York Times. [cited 2023 November 15]. https:\/\/www.nytimes.com\/article\/eye-drops-recall-explained.html."},{"key":"1241_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/jop.2013.0174","volume":"30","author":"CA Rasmussen","year":"2014","unstructured":"Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther. 2014;30:163\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1241_CR68","unstructured":"Bian Y, Kaufman AR, Halfpenny C. Preservatives in topical ophthalmic medications. American Academy of Ophthalmology\u00ae EyeWiki\u00ae. Updated February 23, 2023. https:\/\/eyewiki.aao.org\/Preservatives_in_Topical_Ophthalmic_Medications."},{"key":"1241_CR69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.ico.0000183538.53017.69","volume":"25","author":"C Charnock","year":"2006","unstructured":"Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25:432\u20137.","journal-title":"Cornea"},{"key":"1241_CR70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/17469899.4.1.59","volume":"4","author":"PD Freeman","year":"2009","unstructured":"Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59\u201364.","journal-title":"Expert Rev Ophthalmol"},{"key":"1241_CR71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1167\/iovs.03-0934","volume":"46","author":"K Okabe","year":"2005","unstructured":"Okabe K, Kimura H, Okabe J, Kato A, Shimizu H, Ueda T, et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2005;46:703\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1241_CR72","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000192082","volume":"41","author":"P Pellinen","year":"2009","unstructured":"Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 2009;41:118\u201322.","journal-title":"Ophthalmic Res"},{"key":"1241_CR73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1208\/pt070357","volume":"7","author":"MS Rathore","year":"2006","unstructured":"Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech. 2006;7:57.","journal-title":"AAPS PharmSciTech"},{"key":"1241_CR74","volume":"6","author":"W Chen","year":"2011","unstructured":"Chen W, Li Z, Hu J, Zhang Z, Chen L, Chen Y, et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS ONE. 2011;6:e26103.","journal-title":"PLoS ONE"},{"key":"1241_CR75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.addr.2021.02.008","volume":"171","author":"J Brunner","year":"2021","unstructured":"Brunner J, Ragupathy S, Borchard G. Target specific tight junction modulators. Adv Drug Deliv Rev. 2021;171:266\u201388.","journal-title":"Adv Drug Deliv Rev"},{"key":"1241_CR76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/ICO.0b013e3181a3c3e6","volume":"29","author":"M Kusano","year":"2010","unstructured":"Kusano M, Uematsu M, Kumagami T, Sasaki H, Kitaoka T. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea. 2010;29:80\u20135.","journal-title":"Cornea"},{"key":"1241_CR77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2007.08.017","volume":"348","author":"S Majumdar","year":"2008","unstructured":"Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 2008;348:175\u20138.","journal-title":"Int J Pharm"},{"key":"1241_CR78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1248\/bpb.33.107","volume":"33","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Teshima M, Kitahara T, Sasaki H, Uematsu M, Kitaoka T, et al. Sensitive and real-time method for evaluating corneal barrier considering tear flow. Biol Pharm Bull. 2010;33:107\u201310.","journal-title":"Biol Pharm Bull"},{"key":"1241_CR79","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-021-01731-9","volume":"38","author":"P Harasymowycz","year":"2021","unstructured":"Harasymowycz P, Hutnik C, Rouland JF, Negrete FJM, Economou MA, Denis P, et al. Preserved versus preservative-free latanoprost for the treatment of glaucoma and ocular hypertension: a post hoc pooled analysis. Adv Ther. 2021;38:3019\u201331.","journal-title":"Adv Ther"},{"key":"1241_CR80","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","volume":"97","author":"JF Rouland","year":"2013","unstructured":"Rouland JF, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196\u2013200.","journal-title":"Br J Ophthalmol"},{"key":"1241_CR81","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2016.1202818","volume":"32","author":"F Aptel","year":"2016","unstructured":"Aptel F, Choudhry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2016;32:1457\u201363.","journal-title":"Curr Med Res Opin"},{"key":"1241_CR82","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jfo.2016.05.006","volume":"39","author":"P Denis","year":"2016","unstructured":"Denis P, Monoprost French Study Group. Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. a multicenter, randomized, controlled study. J Fr Ophtalmol. 2016;39:622\u201330.","journal-title":"J Fr Ophtalmol"},{"key":"1241_CR83","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.18240\/ijo.2021.10.10","volume":"14","author":"JM Kim","year":"2021","unstructured":"Kim JM, Sung KR, Lee JW, Kyung H, Rho S, Kim CY. Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial. Int J Ophthalmol. 2021;14:1539\u201347.","journal-title":"Int J Ophthalmol"},{"key":"1241_CR84","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/IJG.0b013e3182a075e6","volume":"23","author":"M Cucherat","year":"2014","unstructured":"Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23:e69\u201375.","journal-title":"J Glaucoma"},{"key":"1241_CR85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","volume":"97","author":"DG Day","year":"2013","unstructured":"Day DG, Walters TR, Schwartz GF, Mundorf TK, Liu C, Schiffman RM, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013;97:989\u201393.","journal-title":"Br J Ophthalmol"},{"key":"1241_CR86","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.3390\/jcm11123518","volume":"11","author":"M Filippelli","year":"2022","unstructured":"Filippelli M, Campagna G, Ciampa N, Fioretto G, Giannini R, Marino PF, et al. Ocular tolerability of bimatoprost 0.1 mg\/mL preservative-free versus bimatoprost 0.1 mg\/mL with benzalkonium chloride or bimatoprost 0.3 mg\/mL preservative-free in patients with primary open-angle glaucoma. J Clin Med. 2022;11:3518.","journal-title":"J Clin Med"},{"key":"1241_CR87","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/IJG.0000000000001248","volume":"28","author":"F Aptel","year":"2019","unstructured":"Aptel F, Pfeiffer N, Schmickler S, Clarke J, Lavin-Dapena C, Moreno-Montanes J, et al. Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28:498\u2013506.","journal-title":"J Glaucoma"},{"key":"1241_CR88","volume":"9","author":"RRA Bourne","year":"2019","unstructured":"Bourne RRA, Kaarniranta K, Lorenz K, Traverso CE, Vuorinen J, Ropo A. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9:e024129.","journal-title":"BMJ Open"},{"key":"1241_CR89","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00417-010-1397-7","volume":"248","author":"A Shedden","year":"2010","unstructured":"Shedden A, Adamsons IA, Getson AJ, Laurence JK, Lines CR, Hewitt DJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757\u201364.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1241_CR90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/OPTH.S91402","volume":"10","author":"H Uusitalo","year":"2016","unstructured":"Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445\u201354.","journal-title":"Clin Ophthalmol"},{"issue":"Suppl 278","key":"1241_CR91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/aos.15808","volume":"101","author":"AH Nagstrup","year":"2023","unstructured":"Nagstrup AH. The use of benzalkonium chloride in topical glaucoma treatment: an investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells. Acta Ophthalmol. 2023;101(Suppl 278):3\u201321.","journal-title":"Acta Ophthalmol"},{"key":"1241_CR92","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1167\/iovs.10-6134","volume":"52","author":"S Swamynathan","year":"2011","unstructured":"Swamynathan S, Kenchegowda D, Piatigorsky J, Swamynathan S. Regulation of corneal epithelial barrier function by Kruppel-like transcription factor 4. Invest Ophthalmol Vis Sci. 2011;52:1762\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1241_CR93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjo.82.1.39","volume":"82","author":"C Baudouin","year":"1998","unstructured":"Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39\u201342.","journal-title":"Br J Ophthalmol"},{"key":"1241_CR94","first-page":"777","volume":"25","author":"P Hamard","year":"2002","unstructured":"Hamard P, Debbasch C, Blondin C, Brignole F, Loison-Dayma K, Warnet JM, et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J Fr Ophtalmol. 2002;25:777\u201384.","journal-title":"J Fr Ophtalmol"},{"key":"1241_CR95","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00061198-200312000-00008","volume":"12","author":"T Ishibashi","year":"2003","unstructured":"Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486\u201390.","journal-title":"J Glaucoma"},{"key":"1241_CR96","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","volume":"27","author":"P Dubrulle","year":"2018","unstructured":"Dubrulle P, Labbe A, Brasnu E, Liang H, Hamard P, Meziani L, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27:1105\u201311.","journal-title":"J Glaucoma"},{"key":"1241_CR97","first-page":"40","volume":"110","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40\u201363.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1241_CR98","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/archopht.121.6.835","volume":"121","author":"Y Goto","year":"2003","unstructured":"Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121:835\u20139.","journal-title":"Arch Ophthalmol"},{"key":"1241_CR99","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1167\/iovs.11-8775","volume":"53","author":"J Sarkar","year":"2012","unstructured":"Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792\u2013802.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1241_CR100","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s40123-024-00998-9","volume":"13","author":"M Villalba","year":"2024","unstructured":"Villalba M, Sabates V, Orgul S, Perez VL, Swaminathan SS, Sabater AL. Detection of subclinical neurotrophic keratopathy by noncontact esthesiometry. Ophthalmol Ther. 2024;13:2393\u2013404.","journal-title":"Ophthalmol Ther"},{"key":"1241_CR101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jtos.2022.07.007","volume":"26","author":"F Fineide","year":"2022","unstructured":"Fineide F, Lagali N, Adil MY, Arita R, Kolko M, Vehof J, et al. Topical glaucoma medications\u2014clinical implications for the ocular surface. Ocul Surf. 2022;26:19\u201349.","journal-title":"Ocul Surf"},{"key":"1241_CR102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10792-017-0792-z","volume":"39","author":"PA Kestelyn","year":"2019","unstructured":"Kestelyn PA, Kestelyn PG, De Bacquer D, Stevens AM. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. Int Ophthalmol. 2019;39:105\u20139.","journal-title":"Int Ophthalmol"},{"key":"1241_CR103","first-page":"584","volume":"26","author":"I Ahmed","year":"1985","unstructured":"Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26:584\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1241_CR104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","volume":"45","author":"X Zhang","year":"2019","unstructured":"Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45:11\u20138.","journal-title":"Eye Contact Lens"},{"key":"1241_CR105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276\u201383.","journal-title":"Ocul Surf"},{"key":"1241_CR106","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","volume":"106","author":"C Baudouin","year":"1999","unstructured":"Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556\u201363.","journal-title":"Ophthalmology"},{"key":"1241_CR107","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/IJG.0b013e31825af67d","volume":"22","author":"C Boimer","year":"2013","unstructured":"Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730\u20135.","journal-title":"J Glaucoma"},{"key":"1241_CR108","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grierson I, O\u2019Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446\u20132154.","journal-title":"Arch Ophthalmol"},{"key":"1241_CR109","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0161-6420(89)32888-0","volume":"96","author":"MB Sherwood","year":"1989","unstructured":"Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon\u2019s capsule in glaucomatous patients. Ophthalmology. 1989;96:327\u201335.","journal-title":"Ophthalmology"},{"key":"1241_CR110","unstructured":"European Medicines Agency. EMEA public statement on antimicrobial preservatives in ophthalmic preparations for human use. European Sources Online. [cited 2009 August 12]. https:\/\/www.europeansources.info\/record\/emea-public-statement-on-antimicrobial-preservatives-in-ophthamlimc-preparations-for-human-use\/."},{"key":"1241_CR111","volume":"45","author":"A Campolo","year":"2022","unstructured":"Campolo A, Crary M, Shannon P. A review of the containers available for multi-dose preservative-free eye drops. Biomed J Sci Tech Res. 2022;45:2022.","journal-title":"Biomed J Sci Tech Res"},{"key":"1241_CR112","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575\u2013628.","journal-title":"Ocul Surf"},{"key":"1241_CR113","first-page":"1419","volume":"8","author":"M Moshirfar","year":"2014","unstructured":"Moshirfar M, Pierson K, Hanamaikai K, Santiago-Caban L, Muthappan V, Passi SF. Artificial tears potpourri: a literature review. Clin Ophthalmol. 2014;8:1419\u201333.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR114","unstructured":"Gudgel DT. How to put in eye drops. American Academy of Ophthalmology; 2023 [cited May 5, 2023]. https:\/\/www.aao.org\/eye-health\/treatments\/how-to-put-in-eye-drops."},{"key":"1241_CR115","unstructured":"Chaudhary OR. How long can you use prescription eye drops after opening them? American Academy of Ophthalmology. [cited February 23, 2022]. https:\/\/www.aao.org\/eye-health\/ask-ophthalmologist-q\/how-long-after-opening-is-it-safe-to-use-eye-drops."},{"key":"1241_CR116","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s11845-024-03704-7","volume":"193","author":"D Brinkman","year":"2024","unstructured":"Brinkman D, McSwiney T, James M. Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension\u2014an observer blinded active-control trial. Ir J Med Sci. 2024;193:2589\u201395.","journal-title":"Ir J Med Sci"},{"key":"1241_CR117","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4103\/ijo.IJO_165_21","volume":"69","author":"SM Hagras","year":"2021","unstructured":"Hagras SM, Al-Duwailah OKH, Nassief MA, Abdelhameed AG. Crossover randomized study comparing the efficacy and tolerability of preservative-free tafluprost 0.0015% to latanoprost 0.005% in patients with primary open-angle glaucoma. Indian J Ophthalmol. 2021;69:2475\u201380.","journal-title":"Indian J Ophthalmol"},{"key":"1241_CR118","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12325-015-0205-5","volume":"32","author":"P Fogagnolo","year":"2015","unstructured":"Fogagnolo P, Dipinto A, Vanzulli E, Maggiolo E, De Cilla S, Autelitano A, et al. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv Ther. 2015;32:356\u201369.","journal-title":"Adv Ther"},{"key":"1241_CR119","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1120672118785280","volume":"29","author":"M Misiuk-Hojlo","year":"2019","unstructured":"Misiuk-Hojlo M, Pomorska M, Mulak M, Rekas M, Wierzbowska J, Prost M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol. 2019;29:210\u20135.","journal-title":"Eur J Ophthalmol"},{"key":"1241_CR120","volume":"14","author":"JM Kim","year":"2021","unstructured":"Kim JM, Park SW, Seong M, Ha SJ, Lee JW, Rho S, et al. Comparison of the safety and efficacy between preserved and preservative-free latanoprost and preservative-free tafluprost. Pharmaceuticals (Basel). 2021;14:14:501.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1241_CR121","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/jcm13051226","volume":"13","author":"Q Daka","year":"2024","unstructured":"Daka Q, Sustar Habjan M, Meglic A, Perovsek D, Atanasovska Velkovska M, Cvenkel B. Retinal ganglion cell function and perfusion following intraocular pressure reduction with preservative-free latanoprost in patients with glaucoma and ocular hypertension. J Clin Med. 2024;13:1226.","journal-title":"J Clin Med"},{"key":"1241_CR122","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/1120672118805877","volume":"29","author":"A El Ameen","year":"2019","unstructured":"El Ameen A, Vandermeer G, Khanna RK, Pisella PJ. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019;29:645\u201353.","journal-title":"Eur J Ophthalmol"},{"key":"1241_CR123","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/OPTH.S126042","volume":"11","author":"FJ Mu\u00f1oz Negrete","year":"2017","unstructured":"Mu\u00f1oz Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017;11:557\u201366.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR124","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00417-016-3299-9","volume":"254","author":"I Stalmans","year":"2016","unstructured":"Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016;254:1151\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1241_CR125","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/OPTH.S176605","volume":"12","author":"MA Economou","year":"2018","unstructured":"Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol. 2018;12:2399\u2013407.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR126","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s40123-024-01013-x","volume":"13","author":"C Guerin","year":"2024","unstructured":"Chauchat L, Guerin C, Rebika H, Sahyoun M, Collignon N. Real-life study on the efficacy and tolerance of a preservative-free surfactant-free latanoprost eye drop in patients with glaucoma. Ophthalmol Ther. 2024;13:2661\u201377.","journal-title":"Ophthalmol Ther"},{"key":"1241_CR127","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s12325-022-02166-6","volume":"39","author":"F Oddone","year":"2022","unstructured":"Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Hollo G, et al. Switching to preservative-free tafluprost\/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY study according to baseline monotherapy treatment. Adv Ther. 2022;39:3501\u201321.","journal-title":"Adv Ther"},{"key":"1241_CR128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/15569527.2019.1680685","volume":"39","author":"Z Duru","year":"2020","unstructured":"Duru Z, Ozsaygili C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. Cutan Ocul Toxicol. 2020;39:21\u20134.","journal-title":"Cutan Ocul Toxicol"},{"key":"1241_CR129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ceo.12431","volume":"43","author":"I Goldberg","year":"2015","unstructured":"Goldberg I, Graham SL, Crowston JG, d\u2019Mellow G, Australian and New Zealand Glaucoma Interest Group. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol. 2015;43:214\u201320.","journal-title":"Clin Exp Ophthalmol"},{"key":"1241_CR130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jfo.2018.04.012","volume":"41","author":"S Lazreg","year":"2018","unstructured":"Lazreg S, Merad Z, Nouri MT, Garout R, Derdour A, Ghroud N, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naive patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41:945\u201354.","journal-title":"J Fr Ophtalmol"},{"key":"1241_CR131","volume":"17","author":"W Lee","year":"2017","unstructured":"Lee W, Lee S, Bae H, Kim CY, Seong GJ. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study. BMC Ophthalmol. 2017;17:61.","journal-title":"BMC Ophthalmol"},{"key":"1241_CR132","first-page":"1967","volume":"8","author":"A Alm","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967\u201385.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR133","first-page":"261","volume":"4","author":"A Arias","year":"2010","unstructured":"Arias A, Schargel K, Ussa F, Canut MI, Robles AY, Sanchez BM. Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol. 2010;4:261\u20137.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR134","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/aos.15715","volume":"102","author":"D Amiri","year":"2024","unstructured":"Amiri D, Sessa M, Andersen M, Kolko M. Persistence and adherence with latanoprost: a Danish register-based cohort study in older patients with glaucoma. Acta Ophthalmol. 2024;102:172\u20138.","journal-title":"Acta Ophthalmol"},{"key":"1241_CR135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/OPTH.S295821","volume":"15","author":"C Erb","year":"2021","unstructured":"Erb C, Stalmans I, Iliev M, Munoz-Negrete FJ. Real-world study on patient satisfaction and tolerability after switching to preservative-free latanoprost. Clin Ophthalmol. 2021;15:931\u20138.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR136","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtos.2017.03.004","volume":"15","author":"JM Martinez-de-la-Casa","year":"2017","unstructured":"Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, Santiago JL, Moreno-Montanes J, Arriola-Villalobos P, et al. Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. Ocul Surf. 2017;15:723\u20139.","journal-title":"Ocul Surf"},{"key":"1241_CR137","unstructured":"National Institute for Health and Care Excellence (NICE). Glaucoma: diagnosis and management. NICE; 2017 [updated January 26, 2022]. www.nice.org.uk\/guidance\/ng81."},{"key":"1241_CR138","unstructured":"Moore DB, Elhusseiny AM. Sustained release glaucoma delivery systems. American Academy of Ophthalmology\u00ae EyeWiki\u00ae. [updated April 17, 2024]. https:\/\/eyewiki.org\/Sustained_Release_Glaucoma_Delivery_Systems."},{"key":"1241_CR139","unstructured":"DURYSTA\u00ae (bimatoprost intracameral implant) [prescribing information]. Chicago: AbbVie Inc.; 2024."},{"key":"1241_CR140","unstructured":"iDose\u00ae TR (travoprost intracameral implant) [prescribing information]. San Clemente: Glaukos Corp.; 2023."},{"key":"1241_CR141","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s40123-024-00965-4","volume":"13","author":"AM Elhusseiny","year":"2024","unstructured":"Elhusseiny AM, Aref AA. Sustained release therapies with the prostaglandin analogues intracameral implants. Ophthalmol Ther. 2024;13:1833\u20139.","journal-title":"Ophthalmol Ther"},{"key":"1241_CR142","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, Belalcazar S, Thieme H, Goodkin ML, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81:2017\u201333.","journal-title":"Drugs"},{"key":"1241_CR143","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010184","volume":"13","author":"E Takao","year":"2023","unstructured":"Takao E, Ichitani A, Tanito M. Estimation of topical glaucoma medication over-prescription and its associated factors. J Clin Med. 2023;13:184.","journal-title":"J Clin Med"},{"key":"1241_CR144","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393\u20138.","journal-title":"J Glaucoma"},{"key":"1241_CR145","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/IJG.0b013e31816b3001","volume":"17","author":"L Gelb","year":"2008","unstructured":"Gelb L, Friedman DS, Quigley HA, Lyon DW, Tan J, Kim EE, et al. Physician beliefs and behaviors related to glaucoma treatment adherence: the Glaucoma Adherence and Persistency Study. J Glaucoma. 2008;17:690\u20138.","journal-title":"J Glaucoma"},{"key":"1241_CR146","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, Pasina L, Weinreb RN, Nobili A. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023;12:2227\u201340.","journal-title":"Ophthalmol Ther"},{"key":"1241_CR147","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","volume":"11","author":"LJ Katz","year":"2002","unstructured":"Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119\u201326.","journal-title":"J Glaucoma"},{"key":"1241_CR148","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02849799","volume":"20","author":"T Mundorf","year":"2003","unstructured":"Mundorf T, Wilcox KA, Ousler GW 3rd, Welch D, Abelson MB. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther. 2003;20:329\u201336.","journal-title":"Adv Ther"},{"key":"1241_CR149","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11094-019-02038-4","volume":"53","author":"MN Anurova","year":"2019","unstructured":"Anurova MN, Bakhrushina EO, Demina NB, Panteleeva ES. Modern preservatives of microbiological stability (review). Pharm Chem J. 2019;53:564\u201371.","journal-title":"Pharm Chem J"},{"key":"1241_CR150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","volume":"21","author":"M Aihara","year":"2012","unstructured":"Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, et al. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma. 2012;21:60\u20134.","journal-title":"J Glaucoma"},{"key":"1241_CR151","first-page":"613","volume":"2","author":"JC Henry","year":"2008","unstructured":"Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613\u201321.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR152","first-page":"291","volume":"3","author":"MB Horsley","year":"2009","unstructured":"Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291\u20135.","journal-title":"Clin Ophthalmol"},{"key":"1241_CR153","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICL.0000000000000860","volume":"48","author":"D Wirta","year":"2022","unstructured":"Wirta D, Malhotra R, Peace J, Shen Lee B, Mitchell B, Sall K, et al. Noninferiority study comparing latanoprost 0.005% without versus with benzalkonium chloride in open-angle glaucoma or ocular hypertension. Eye Contact Lens. 2022;48:149\u201354.","journal-title":"Eye Contact Lens"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01241-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:03Z","timestamp":1760715723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01241-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":153,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01241-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Deepinder K. Dhaliwal: Consultant\/Advisor: Thea, Bausch\u2009+\u2009Lomb, Johnson & Johnson, Staar Surgical, Aurion Biotech, Scope Eyecare, Tarsus, CSI Dry Eye Software, Epion Therapeutics, Lenz Therapeutics, and EyeYon Medical. Research grants: Bausch\u2009+\u2009Lomb, Epion Therapeutics, Kala. Aakrita G. Shukla: Consultant\/Speaker: Alcon; Consultant: Thea; Consultant: AbbVie. Paul Singh: Consultant: Allergan, Alcon, Bausch\u2009+\u2009Lomb, Glaukos, iSTAR Medical, New World Medical, Nova Eye Medical, and Sight Sciences; Lecture fees: Allergan, Alcon, Bausch\u2009+\u2009Lomb, Glaukos, iSTAR Medical, New World Medical, Nova Eye Medical, Sight Sciences, Thea, and Viatris. Zeba A. Syed: nothing to disclose. Darrell E. White: Consultant: Aldeyra Therapeutics; Speaker\/Consultant: Allergan\/AbbVie; Speaker\/Consultant: Bausch\u2009+\u2009Lomb; Consultant: Bruder; Speaker\/Consultant: Viatris\/Oyster Point Pharma; Speaker\/Consultant: Sun Ophthalmics; Consultant: Tarsus; Speaker\/Consultant\/ Investor: Orasis Pharmaceuticals: Speaker\/Consultant: Nordic Pharma; Consultant\/Investor: SpyGlass Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}